Femto-LASIK outperformed

Article

Moria's new microkeratome, One Use-Plus SBK, outperforms Femto-LASIK, it was announced at this year's meeting of the American Society of Cataract and Refractive Surgery (ASCRS).

Moria's new microkeratome, One Use-Plus SBK, outperforms Femto-LASIK, it was announced at this year's meeting of the American Society of Cataract and Refractive Surgery (ASCRS).

Richard J. Duffey, MD of Premier Medical Eye Group, Alabama, US compared flap thickness predictability, speed of visual recovery, higher order aberrations, smoothness of stromal bed and patient comfort between the two techniques. Dr Duffey has no financial interest in Moria or the One Use-Plus SBK.

For every variable, the One Use-Plus compared equally or favourably with Femto-LASIK, with none of the associated complications of the latter device. Postoperative pain in the first one to five hours was lower in both frequency and intensity when using the One Use-Plus than with Femto-LASIK.

Dr Duffey concluded that the One Use-Plus was a better option for both patients and surgeons than Femto-LASIK.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.